EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial

Maria E Cabanillas, Naifa L Busaidy, Mark Zafereo, Priyanka C Iyer, Jennifer R Wang, Sarah Hamidi, Renata Ferrarotto, Suyu Liu, Gary B Gunn, Michael Spiotto, Anna Lee, Anastasios Maniakas und 7 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.117013 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Maria E Cabanillas und 18 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: mcabani@mdanderson.org. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Phenylurea Compounds, Thyroid Carcinoma, Anaplastic, Quinolines. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gateway for Cancer Research, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPhenylurea CompoundsThyroid Carcinoma, AnaplasticQuinolinesAntineoplastic Combined Chemotherapy ProtocolsThyroid NeoplasmsHumansMaleMiddle AgedFemaleAgedMutationAdultProto-Oncogene Proteins B-rafAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

BRAF wild-typeImmune checkpoint inhibitorImmunotherapyMultikinase inhibitorTargeted therapyTyrosine kinase inhibitorUndifferentiated thyroid cancer

Substanzen

Antibodies, Monoclonal, HumanizedlenvatinibPhenylurea CompoundsQuinolinespembrolizumabProto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: mcabani@mdanderson.org.
  • The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Förderung

  • Gateway for Cancer Research
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Cabanillas, M. E., Busaidy, N. L., Zafereo, M., Iyer, P. C., Wang, J. R., Hamidi, S., Ferrarotto, R., Liu, S., Gunn, G. B., Spiotto, M., Lee, A., Maniakas, A., Gule-Monroe, M., Williams, M. D., Hosseini, S. M., Banuchi, V. E., Hu, M. I., Ning, M., & Dadu, R. (2026). Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117013

Vancouver

Cabanillas ME, Busaidy NL, Zafereo M, Iyer PC, Wang JR, Hamidi S, et al. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117013

BibTeX
@article{Cabanillas2026,
  author = {Cabanillas, Maria E and Busaidy, Naifa L and Zafereo, Mark and Iyer, Priyanka C and Wang, Jennifer R and Hamidi, Sarah and Ferrarotto, Renata and Liu, Suyu and Gunn, Gary B and Spiotto, Michael and Lee, Anna and Maniakas, Anastasios and Gule-Monroe, Maria and Williams, Michelle D and Hosseini, S Mohsen and Banuchi, Victoria E and Hu, Mimi I and Ning, Matthew and Dadu, Ramona},
  title = {Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.117013}
}
Kostenlos starten →